Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
 - EconoTimes)
NEW ORLEANS, March 17, 2017 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., reminds investors that they have until March 27, 2017 to file lead plaintiff applications in a securities class action lawsuit against PixarBio Corporation (Other OTC:PXRB), if they purchased the Company’s securities pursuant and/or traceable to PixarBio’s private placement that closed on October 30, 2016 and/or between October 31, 2016 and January 20, 2017, inclusive (the “Class Period”). The action is pending in United States District Court for the District of New Jersey.
What You May Do
If you purchased securities of PixarBio and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by March 27, 2017.
About the Lawsuit
PixarBio and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the market for PixarBio’s securities exhibited manipulative or deceptive activities; and (ii) PixarBio’s assertions in press releases, third-party promotional materials, and PixarBio’s Form S-1 concerning, among other things, PixarBio’s business combinations and current shareholders; the identity and qualifications of key shareholders and employees and PixarBio’s current and prospective development efforts were untrue.
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
